Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jun 1;2017(2):2141-2148. doi: 10.1200/JCO.2016.70.8297.2017.2.test.

PMID:
29629819
2.

IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.

Cardillo TM, Govindan SV, Zalath MB, Rossi DL, Wang Y, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2018 Jan;17(1):150-160. doi: 10.1158/1535-7163.MCT-17-0354. Epub 2017 Nov 13.

PMID:
29133623
3.

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130).

Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2018 Jan;17(1):196-203. doi: 10.1158/1535-7163.MCT-17-0442. Epub 2017 Oct 27.

PMID:
29079710
4.

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.

Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD.

J Clin Oncol. 2017 Oct 10;35(29):3338-3346. doi: 10.1200/JCO.2017.73.9011. Epub 2017 Aug 17.

PMID:
28817371
5.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.

Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2017 Oct 1;23(19):5711-5719. doi: 10.1158/1078-0432.CCR-17-0933. Epub 2017 Jul 5.

PMID:
28679770
6.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

PMID:
28558150
7.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR.

J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.

PMID:
28548889
8.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

PMID:
28291390
9.

Prospects and progress of antibody-drug conjugates in solid tumor therapies.

Govindan SV, Sharkey RM, Goldenberg DM.

Expert Opin Biol Ther. 2016 Jul;16(7):883-93. doi: 10.1517/14712598.2016.1173203. Epub 2016 May 3. Review.

PMID:
27045979
10.

Meta-Analyses of Microarray Datasets Identifies ANO1 and FADD as Prognostic Markers of Head and Neck Cancer.

Reddy RB, Bhat AR, James BL, Govindan SV, Mathew R, Ravindra DR, Hedne N, Illiayaraja J, Kekatpure V, Khora SS, Hicks W, Tata P, Kuriakose MA, Suresh A.

PLoS One. 2016 Jan 25;11(1):e0147409. doi: 10.1371/journal.pone.0147409. eCollection 2016.

11.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST.

Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.

12.

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).

Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM.

Clin Cancer Res. 2015 Nov 15;21(22):5131-8. doi: 10.1158/1078-0432.CCR-15-0670. Epub 2015 Jun 23.

13.

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).

Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM.

Oncotarget. 2015 Sep 8;6(26):22496-512.

14.

Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.

Govindan SV, Kulsum S, Pandian RS, Das D, Seshadri M, Hicks W Jr, Kuriakose MA, Suresh A.

Mol Med Rep. 2015 Aug;12(2):3025-32. doi: 10.3892/mmr.2015.3768. Epub 2015 May 12.

PMID:
25962396
15.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, Hamburger SA, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2015 Sep 1;21(17):3870-8. doi: 10.1158/1078-0432.CCR-14-3321. Epub 2015 May 5.

16.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang CH, Goldenberg DM.

Bioconjug Chem. 2015 May 20;26(5):919-31. doi: 10.1021/acs.bioconjchem.5b00223. Epub 2015 May 8.

PMID:
25915780
17.

Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.

Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM.

Mol Pharm. 2015 Jun 1;12(6):1836-47. doi: 10.1021/mp5006195. Epub 2014 Nov 25.

PMID:
25402018
18.

Factors predicting outcome after salvage treatment for stage IV oral squamous cell carcinoma: Evidence of the potential importance of the cyclooxygenase-2-prostaglandin E2 pathway.

Kekatpure VD, Singh M, Selvam S, Shetkar G, Hedne NC, Trivedi NP, Siddappa G, Govindan SV, Suresh A, Rangarajan B, Dannenberg AJ, Kuriakose MA.

Head Neck. 2015 Aug;37(8):1142-9. doi: 10.1002/hed.23721. Epub 2014 Nov 15.

PMID:
24771596
19.

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM.

Mol Cancer Ther. 2013 Jun;12(6):968-78. doi: 10.1158/1535-7163.MCT-12-1170. Epub 2013 Feb 20.

20.

Designing immunoconjugates for cancer therapy.

Govindan SV, Goldenberg DM.

Expert Opin Biol Ther. 2012 Jul;12(7):873-90. doi: 10.1517/14712598.2012.685153. Review.

PMID:
22679911
21.

Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.

Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM.

Mol Cancer Ther. 2012 Jan;11(1):224-34. doi: 10.1158/1535-7163.MCT-11-0632. Epub 2011 Oct 28.

22.

Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.

Sharkey RM, Karacay H, Govindan SV, Goldenberg DM.

Mol Cancer Ther. 2011 Jun;10(6):1072-81. doi: 10.1158/1535-7163.MCT-11-0115. Epub 2011 Apr 5.

23.

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys.

Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM.

Clin Cancer Res. 2011 May 15;17(10):3157-69. doi: 10.1158/1078-0432.CCR-10-2939. Epub 2011 Mar 3.

24.

New antibody conjugates in cancer therapy.

Govindan SV, Goldenberg DM.

ScientificWorldJournal. 2010 Oct 12;10:2070-89. doi: 10.1100/tsw.2010.191. Review.

25.

Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806.

Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, Sagona J, Rigopoulos A, Smyth FE, Johns TG, Govindan SV, Goldenberg DM, Old LJ, Scott AM.

J Nucl Med. 2010 Jun;51(6):967-72. doi: 10.2967/jnumed.109.068395. Epub 2010 May 19.

26.

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates.

Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2009 Oct 1;15(19):6052-61. doi: 10.1158/1078-0432.CCR-09-0586. Epub 2009 Sep 29.

27.

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.

Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM.

J Med Chem. 2008 Nov 13;51(21):6916-26. doi: 10.1021/jm800719t. Epub 2008 Oct 22.

28.

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.

Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, Goldenberg DM.

Clin Cancer Res. 2005 Jul 15;11(14):5257-64.

29.

Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.

Govindan SV, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM.

Technol Cancer Res Treat. 2005 Aug;4(4):375-91. Review.

PMID:
16029057
30.

Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates.

Govindan SV, Michel RB, Griffiths GL, Goldenberg DM, Mattes MJ.

Nucl Med Biol. 2005 Jul;32(5):513-9.

PMID:
15982582
31.

Development of humanized antibodies as cancer therapeutics.

Qu Z, Griffiths GL, Wegener WA, Chang CH, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.

Methods. 2005 May;36(1):84-95.

PMID:
15848077
32.

Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.

Stein R, Govindan SV, Hayes M, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM.

Clin Cancer Res. 2005 Apr 1;11(7):2727-34.

33.

Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.

Govindan SV, Griffiths GL, Stein R, Andrews P, Sharkey RM, Hansen HJ, Horak ID, Goldenberg DM.

J Nucl Med. 2005 Jan;46(1):153-9.

34.

Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.

Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM.

Breast Cancer Res Treat. 2004 Mar;84(2):173-82.

PMID:
14999147
35.

Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.

Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 2003 Dec 15;9(17):6567-71.

36.

Improved iodine radiolabels for monoclonal antibody therapy.

Stein R, Govindan SV, Mattes MJ, Chen S, Reed L, Newsome G, McBride BJ, Griffiths GL, Hansen HJ, Goldenberg DM.

Cancer Res. 2003 Jan 1;63(1):111-8.

37.

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.

J Nucl Med. 2003 Jan;44(1):77-84.

38.

Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.

Govindan SV, Griffiths GL, Michel RB, Andrews PM, Goldenberg DM, Mattes MJ.

Cancer Biother Radiopharm. 2002 Jun;17(3):307-16.

PMID:
12136523
39.

Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.

Stein R, Govindan SV, Chen S, Reed L, Spiegelman H, Griffiths GL, Hansen HJ, Goldenberg DM.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):173-80.

PMID:
11418314
40.
41.

Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters.

Govindan SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, Sgouros G, Mattes MJ.

J Nucl Med. 2000 Dec;41(12):2089-97.

42.

Advances in the use of monoclonal antibodies in cancer radiotherapy.

Govindan SV, Goldenberg DM, Hansen HJ, Griffiths GL.

Pharm Sci Technolo Today. 2000 Mar;3(3):90-98.

PMID:
10707044
43.

Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.

Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3079s-3087s.

PMID:
10541347
44.

Cytotoxicity with Auger electron-emitting radionuclides delivered by antibodies.

Griffiths GL, Govindan SV, Sgouros G, Ong GL, Goldenberg DM, Mattes MJ.

Int J Cancer. 1999 Jun 11;81(6):985-92.

45.

Labeling of monoclonal antibodies with diethylenetriaminepentaacetic acid-appended radioiodinated peptides containing D-amino acids.

Govindan SV, Mattes MJ, Stein R, McBride BJ, Karacay H, Goldenberg DM, Hansen HJ, Griffiths GL.

Bioconjug Chem. 1999 Mar-Apr;10(2):231-40.

PMID:
10077472
46.

90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.

Govindan SV, Shih LB, Goldenberg DM, Sharkey RM, Karacay H, Donnelly JE, Losman MJ, Hansen HJ, Griffiths GL.

Bioconjug Chem. 1998 Nov-Dec;9(6):773-82.

PMID:
9815172
47.

Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.

Qu Z, Sharkey RM, Hansen HJ, Shih LB, Govindan SV, Shen J, Goldenberg DM, Leung SO.

J Immunol Methods. 1998 Apr 15;213(2):131-44.

PMID:
9692846
48.

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.

Karacay H, Sharkey RM, Govindan SV, McBride WJ, Goldenberg DM, Hansen HJ, Griffiths GL.

Bioconjug Chem. 1997 Jul-Aug;8(4):585-94.

PMID:
9258459
49.

The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.

Mattes MJ, Shih LB, Govindan SV, Sharkey RM, Ong GL, Xuan H, Goldenberg DM.

Int J Cancer. 1997 May 2;71(3):429-35.

50.

Thiolations, 99mTc labelings, and animal in vivo biodistributions of divalent monoclonal antibody fragments.

Govindan SV, Goldenberg DM, Grebenau RC, Hansen HJ, Griffiths GL.

Bioconjug Chem. 1996 May-Jun;7(3):290-7.

PMID:
8816950

Supplemental Content

Loading ...
Support Center